This study is a phase IIa single-center, single-arm, open-label, clinical study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of HER2- positive advanced melanoma. HER2 positive is defined as the expression of HER2 protein in the primary tumor or metastatic tumor tissue as IHC 2+ or IHC 3+ by immunohistochemistry (IHC).
This is a Phase IIa, single-arm, single-center, open-label clinical trial aims to evaluate the effectiveness and safety of RC48-ADC in the treatment of HER2-positive advanced melanoma.